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ProposaI for a
COUNCIL DIRECTIVE
amending Directives 65l65/EEC and 75/319/EEC on
the approximation of provisions Laid down by Law,
reguLation or administrative action reLating to
proprietary medi cinaL products
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1 .. The na·dtHii:il pr,:JvisiO~"''ii •"t-';.atin(i tothe impt:.""i:: and mar:<et;rlg cf 
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. ~'>~''oprietary medicina~ pru·j•Jcts have ·been the s•.1bject of a series o~ 
Co:Jncil Directives (65/65/EEC of 26 January 1965, 75/318/F.E.C anci 
/ 
75/319/EEC of 20 May 1975> • 
In 
the 
a judgment of 26 M_ay 1976 (Case .104/75 (De Peijper) · C1976] ECR 6~3).,., 
Court of Justic.e was called upon to decide on the compatibHity"wi'!:h·: 
the Treaty, and in particular with Articles 30 et seq., of cert~in · 
national practices which Lead to dhannelling ~mports in such a way that 
only certain economic operators can undertake them, others beir,g excluded 
f.rom doing so. 
In-accordance with the Court's judgment, steps must be taken to ~tevent 
the regulations and practices allowing "the manufacturer of the 
~harmaceutical product in questibn and his duly ap~ofnt~d' representative~; 
simply by refusing to produce.the documents relating to the medicinal 
preparation· in general or to' a specific batch of that preparation, to 
·enjoy a monopoly of the importing and ·marketing of the product." It must•. 
also be ensured that the health and life of perspns can beprotected 
effectively by measures which are less restrictive to int~a-Community 
trade without it "obviously being beyond the means which can reasonably 
be expected of an administration oper~ting in a normal manner". 
/: 3. It appears that the Membe~ St~tes have not all· drawn the· sam~ ~onclusions · 
from this judgment of the Cou.rt of Justice. Some have amended their laws; 
others, without am~nding them, have been tacitly in favour of removing 
! ' 
j 
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'I 
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' i 
the monopoly position in respect of the import and marketing of 
proprietary med~~~hal products of the manufact~rer and his approved 
representatives I 
-Under these conditions, even if, as the Court has potnted out, the Member 
States cannot invoke directives in order to avoid ~he obligations laid 
' 
down in the Treaty, it seems advisable to supplement the Community 
Directives. in order to remove the barriers. 
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. supptemented by a system of registration of parallel importers: the 
· paralle~ importers are .registered as the persons .responsible for marketi':'g 
when the p~oduct imported-and the product authorized _are identical 
Cfi rst. subparagraph of Article 1(4)). Thus·, one can draw a clear 
distinction between the. product whic.h receives a marketing authorizatio_nj 
and the persons responsible for· its marketing, who are reg·i stered. 
The applicant for re·gi str.ation supplies the information he has readily 
avaHable <second subparagraph ·of .Article 1<4)). 
The competent authori'y will be able to examine without delay the 
conformity of the product imported in patallet with the authorized 
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I 
l. 
product: it will be obligatory for the applicant for the marketing ! 
authorization t·o show in his file any .changes made to the ,product in thel 
various Member States and to supply the particulars and.documents 
concerning such changes and to keep his f.ile up to date (Article 1<1)) •. 
l ! s. In order to avoid purely formal changes in products, which would make 
the supervision o.f the market that devolves on the competent authoritiesi I I· 
I 
l 
l 
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in accordanc~ with the provisions of Chapter V of Directive 75/319/EEC 1 
1 
more difficult, new cases for refusal of. authorization to market are · 1 
propOsed in Article 1<2> arid (3): 
1
changes in composition m~st be justified 
therapeutically,· chang~~ of name ~ust be.for legitimate reasons and must: 
not cause any risk of confu~ion or. lead.to mistakes as to the qualities i-j 
or properties of the .product. .- i I. 
! . 
; 6. After the person responsible for marketing has been registered, the·. 
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authorities must st-ill be able to check at any time and ascertain whether 
the imported-medicine is in conformity with the particulars shown in the: 
, file. In the case of product's imported by the manufactarer or the approved 
importer, this _conformity is proved by the control reports signed by t.hef 
- ' 
qualified person, which accompany 'the product. In the case of produ:ets 
.. imported in paraUel, other Methods o.f proof are provided for fn 
Article 1<2> at the discretion of .the person responsible for marketing. 
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) THE COUNCI-L- OF THE EUROPEAN COMMUNITIES, I' 
Havfng. 'regard to the Treaty establishing .the· European Economic Community,· I _ 
_ ;_and in partic:u~ar A~tic:le 100 thereof., 
I 
i 
; Having regard to the proposal ffom the Commission, 
· l. Having regard to the opinion o'f the European Parliament, 
·I. . -- ! 
. ; Having regard to the opinion of the Economic and Social Committee, 
:Whereas Article 4 of Council Directive 65/65/~Ec 1 as amended 
! by Directive 75/319/EEC2 provides that in order 
I 
; to obt~in marketing authorization the person responsible- for marketing 
i shall make an application to the competent authority of the_Member State 
concerned; whereas Article 22 of- Directive 75/319/EEC as amended by 
:_Directive 78/420/EEC-3 makes exemption from.contr9ls subject to the 
·presentation of control reports signed by the qualified person; 
: Whereas it is advisable to prev_ent the manufacturer from be)ng able to 
~monopolize the importation and marketing of proprietary medicinal products 
' -~ by merely refusing to produce the documents relating to the proprietary 
! product in general or to: a specific batch of that proprietary product; 
' 
,! 
' 
. Whereas it is consequ~ntly necessary to supplement the provisions of 
) 
'Directive 65/65/EEC to allow the registratiQn of parallel importer~ as 
: persons responsible for. marketing, whi eh is. necessary for the proper· 
I supervision of the market by the competent authorities; whereas, in order 
:to avoid purely formal changes_ in proprietary medicinal products, it- is 
:also advisable to provide for new cases of refusal of marketing 
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: authorization; 
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: 10J NO 22, 9 
i 20J NO L 147, 
' ~ 30J NO L 123, 
l 
1 
' : 
February 1965, p.369/65 
9 June 1975, p.13 
11 May 1978, p.26 
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Whereas it _is necessary to araend t~e provisions of Directive 75/319/EEC. to 
facilitate proof of the conformityJof the imported, proprietary product with 
the particulars shown in the file,. 
HAS ADOPTEO THIS DIRECTI~: 
Article 1 
Directive 65/65/EEC shall be amended as follows: 
1. Point 11 of the secotid par,agraph of Article ·4 shall be replaced by the 
following: 
"'1t. An authorization obtained in another Membe,- State or in a non-member 
country to place the relevant proprietary medicinal product on the 
·market, provided that such authorization exists, with specification 
of the changes made to this proprietar,y product in the various · 
Member States and· the parti.culars and documents concerning such 
changes.'! 
2. The following .two paragraphs shall be added to Article 4: 
. . 
"The holder o·f the marketing authorization' shall forthwith communicate 
to the competent authorities any new factor which involves a change 
in the particulars and documents listed in the second paragraph on any 
additional instruction, and in particular any prohibition or restriction 
laid down by the competent authorities of the States where the medicine 
is f!18rketed • 
' The holder of 1:he marketing authorization shall ·forthwith commun·i cate 
t~ the competent authorities any amendment which he proposes to make to 
the partic~lars and docum~nts listed in the second paragraph." 
3. The first paragraph of·Article 5 shall be replaced by the following: 
"The ·authorization provided for in Article 3 shall be refused if, after 
verification of the particulars and documents listed in Article 4, it 
proves that the proprietary medicinal product .is harmful in the 
normal conditions of use, or that-its therapeutic efficacy is lacki.ng 
or is insufficiently substantiated by the applicant, or that its 
qualitative or quantitative composition i'S not as declared, or that 
the qualitative or quantitative composition of the proprietary product 
has been changed, without therapeutic justification, compared with 
that authorized in another Melftber State ... 
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1 ~. The following third paragraph shall be ~dded to Article 5: 
"Lastly# marketing authorization shall be refused if the name of the 
proprietary product risks·causing confusion with a proprietary product 
which has already been registered and which has a different qualitative 
composition a~ far as the active principles are·concerned, or if the 
n~me of the proprietary product is 'liable to i~duce misunderstandings 
as to its qual·ities on· properties, or if the name requested ·is d1fferent 
from that used in the other Member States for the same proprietary 
product, unless legitimate reasons justify the use.of such different 
name." 
' 5. The following Articles 10a· and 10b shall be inserted after Article 10: 
,•". I' (I' 
"Article 10? 
The competent authorities shall register the other persons.responsible 
for marketing who so request, within 45 days of such r"equest, except 
' 
where the proprietary produc·t they wish to place on the market is not 
authorized in the Member State from which it comes"br if it has not been manu-
factured by the same manufacturer or the same group of manufacturers o~ 
if, in comparison with the authorized proprietary product, it presents 
differences which affect its therapeutic effect or harmfulness. 
·The following particulars shall be appended to this request: 
1. Name or business ~ame and address of the person responsibl~ 
for placing the product ~n the market, 
'' 
' ' 
2. Member State from which· the'proprietary product to be· imported comes, 
i. 
. 
3. Name of the prbprietary product in.the M~mber State from which it 
. 
comes and number of the marketing authorization, 
4. Name of the proprietary product. in _the Member ·state to which the· 
appl i cat.ion for regi stra~ion 1 s addressed and Aumber of the marketing. 
authorization, 
·s. Pharmaceutical form. 
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Article 10 b 
, . 
' The competent authorities s"atl cancel the registration provided for in~ 
·· Arti.de 10 a where it appe.ars that the proprietary medi cin~l product in· 
. . 
question no ·tong-er sat11f1es the ;condition• r•ferred to in that Article~·., 
The first' sentnec.e of th-e fi.rst p~ragrap'h of Articte 12 shalt be 
repta:e::ed by the f.ottowing: 
••At \. decisions taken pursuant to ~rti cles S, ~, 1tla, 10b .and 11 
sta~e in deta-il the reasons oh _w,ich they are based." 
i 
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I Artit:te 2 ~~....-;;..;;.;;;;~ ' !· 
I -
.The following Article 22a shalt be 
/ 
inserted after Articte 22 of 
i 
·I Directive 75/319/EEC: · 
l ' 
,. . "Articte 22 a -
., 
' 
.: 
,-
1. Where the person responsible for marketing pursuant to Articte 
. 10a does not have: tne controt reports referred to in the .se.cond .sub .. 
paragraph of Art_; C.-Le -22( 1), he ~Y require f.rom t~e competent aut-hori t i-~s: 
<a> that the control reports be supplied to him; 
·(b) that-the controls deter~ined by the competent authorities in 
accordance with the provisions of this thapter be carried out; 
(c) that tbe COntrols be carf'i.ed out by a laboratory designated for 
this purpose by the coapetent .authorities. 
2 .• Me-11ber States -shall adopt alt appropriate provisions to enSlJre that 
the· manufacturer suppties them forthwith, ~ r~quest, with the 
controt. report-s·, referred to in f)ar~raph 1 
. I 
for any batch or part of a batch of proprietary products. 
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3. Upon request; thl. competent' 'authorities concerned shall forthwith 
communicate to each other the control reports referred to in 
paragraph 1." 
Ard c le 3 
Member States shall bring into force the provisions necessary in order to 
comply with this Directive within six months of its notification and shall 
forthwith inform the Commission thereof • 
Member States shall communicate to the Commission the text of the provisions 
of national law which they adopt in the. field covered by ~his Directive. 
Article 4 
. ' 
This.Directive is addressed to the Member States. 
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